Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
iboga alkaloid |
| gptkbp:CASNumber |
138404-24-9
|
| gptkbp:clinicalTrialPhase |
Phase II (as of 2023)
|
| gptkbp:developedBy |
treatment of addiction
MindMed |
| gptkbp:discoveredBy |
Stanley D. Glick
|
| gptkbp:effect |
reduces self-administration of addictive drugs in animal models
|
| gptkbp:hasInChIKey |
QJQYQKZQJZKJQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C22H28N2O2
|
| gptkbp:hasPatent |
US Patent 5,854,288
|
| gptkbp:hasSMILES |
COc1ccc2c3c1OCC4CCN(CC4)C3CC5=C2NC6=CC=CC=C56
|
| https://www.w3.org/2000/01/rdf-schema#label |
18-MC
|
| gptkbp:IUPACName |
18-methoxycoronaridine
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
alpha3beta4 nicotinic acetylcholine receptor antagonist
|
| gptkbp:molecularWeight |
352.47 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL2103832
5311066 |
| gptkbp:relatedTo |
gptkb:ibogaine
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fewer side effects than ibogaine
|
| gptkbp:synonym |
18-MC HCl
18-MC hydrochloride 18-methoxycoronaridine 18-methoxycoronaridine hydrochloride |
| gptkbp:UNII |
6QK1I0Y5F7
|
| gptkbp:bfsParent |
gptkb:Mind_Medicine
gptkb:noribogaine |
| gptkbp:bfsLayer |
7
|